Theranostics
Lutetium-177 Radioligand Therapy (Theranostics) for Prostate Cancer
Targeted, personalized treatment for advanced prostate cancer—delivered by specialists in prostate cancer.
At the Prostate Cancer Institute of America (PCIA), we partner with urologists to bring patients access to Lutetium-177–based radioligand therapy (RLT), which includes agents such as Pluvicto®.
This therapy is a form of theranostics, pairing diagnostic imaging with targeted therapy to deliver precision radiation directly to prostate cancer cells while sparing surrounding healthy tissue.
Exclusivity and Expertise
- Requires specialized licensing & training – Not all radiation oncologists are authorized to deliver Pluvicto®. It demands advanced training in theranostics, safety protocols, and radiopharmaceutical handling.
- We partner with urologists – Ensuring seamless co-management, rapid eligibility review, and shared follow-up data. We protect and enhance the physician-patient relationship through collaborative care.
- Only available at select licensed sites – PCIA physicians work at approved centers with the infrastructure and regulatory clearance to administer therapy safely.
Who is a candidate for Lu-177 Radioligand (Pluvicto®) therapy?
You may be eligible if you have:
- Metastatic castration-resistant prostate cancer (mCRPC)
- Progression of disease (rising PSA) despite ongoing androgen deprivation therapy (hormones)
- Disease confirmed to be PSMA-positive on PET scan
- Adequate bone marrow, kidney, and liver function
Why choose Pluvicto® over chemotherapy or second-line hormonal therapy?
Pluvicto® has been shown in major clinical trials to:
- Extend survival in men with PSMA-positive advanced prostate cancer
- Delay disease progression more effectively than standard next-line options
- Maintain a better quality of life with fewer side effects compared to chemotherapy or additional hormone therapy
Ready to explore if Pluvicto® is right for you or your patient?
schedule a consultation, or connect with our team today.
